Stock RPRX ROYALTY PHARMA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
28 USD -0.39% Intraday chart for Royalty Pharma plc -0.57% -0.32%
Apr. 17 Royalty Pharma Maintains Quarterly Dividend at $0.21 per Share, Payable June 14 to Shareholders of Record May 17 MT
Apr. 17 Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 19,426 17,116 17,432 12,497 12,627 - -
Enterprise Value (EV) 1 23,181 22,089 22,814 18,155 18,378 18,556 18,400
P/E ratio 31.2 x 39 x 558 x 11.1 x 11.9 x 10.3 x 9.43 x
Yield 0.6% 1.71% 1.92% 2.85% 3.14% 3.42% 3.35%
Capitalization / Revenue 9.15 x 7.48 x 7.79 x 5.31 x 4.75 x 4.28 x 3.97 x
EV / Revenue 10.9 x 9.65 x 10.2 x 7.71 x 6.91 x 6.29 x 5.79 x
EV / EBITDA 14.3 x 11.4 x 8.89 x 6.47 x 7.4 x 6.77 x 6.14 x
EV / FCF 11.4 x 12.5 x 10.2 x 6.7 x 19.4 x 14.8 x 12.5 x
FCF Yield 8.78% 8% 9.8% 14.9% 5.15% 6.75% 8.02%
Price to Book 3.07 x 2.36 x 2.52 x 1.66 x 1.26 x 1.16 x 1.06 x
Nbr of stocks (in thousands) 388,132 429,511 441,104 444,886 450,981 - -
Reference price 2 50.05 39.85 39.52 28.09 28.00 28.00 28.00
Announcement Date 2/17/21 2/15/22 2/15/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,122 2,289 2,237 2,355 2,659 2,948 3,179
EBITDA 1 1,621 1,944 2,566 2,806 2,483 2,740 2,995
EBIT 1 1,598 1,921 2,560 2,806 2,148 2,391 2,711
Operating Margin 75.31% 83.92% 114.44% 119.14% 80.8% 81.11% 85.26%
Earnings before Tax (EBT) 1 - - 230 1,700 1,321 1,734 -
Net income 1 975 620 43 1,135 1,054 1,204 1,295
Net margin 45.95% 27.09% 1.92% 48.2% 39.63% 40.83% 40.73%
EPS 2 1.606 1.021 0.0708 2.530 2.353 2.710 2.970
Free Cash Flow 1 2,035 1,767 2,235 2,708 947 1,253 1,475
FCF margin 95.88% 77.18% 99.92% 115% 35.62% 42.5% 46.39%
FCF Conversion (EBITDA) 125.52% 90.88% 87.11% 96.51% 38.14% 45.72% 49.25%
FCF Conversion (Net income) 208.68% 284.94% 5,198.2% 238.6% 89.87% 104.09% 113.9%
Dividend per Share 2 0.3000 0.6800 0.7600 0.8000 0.8796 0.9566 0.9379
Announcement Date 2/17/21 2/15/22 2/15/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 586 576 562 536 573 566 684 538 536.3 596 694.6 628.8 694.2 662.9 -
EBITDA 1 533 494 556 480 548 983 1,044 498 582.2 682 637.6 589.6 648.2 605.4 701
EBIT 1 527 488 550 480 548 983 1,044 498 582.2 681.7 541.2 463.8 481.5 561.5 -
Operating Margin 89.93% 84.72% 97.86% 89.55% 95.64% 173.67% 152.63% 92.57% 108.56% 114.38% 77.92% 73.76% 69.36% 84.7% -
Earnings before Tax (EBT) - - - - - - - - - - - - - - -
Net income 1 102 8 52 305 143 -456 - - - 494 239.6 -6.24 46.86 484.2 -
Net margin 17.41% 1.39% 9.25% 56.9% 24.96% -80.57% - - - 82.89% 34.5% -0.99% 6.75% 73.04% -
EPS 2 0.1680 0.0132 0.0857 0.5025 0.2360 -0.7512 - - - 1.100 0.5400 -0.0100 0.1000 1.080 -
Dividend per Share 2 0.1700 - - 0.1900 0.1900 0.1900 0.2000 0.2000 0.2000 0.2000 0.2100 0.2100 0.2100 0.2079 -
Announcement Date 11/10/21 2/15/22 5/5/22 8/4/22 11/8/22 2/15/23 5/9/23 8/8/23 11/8/23 2/15/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 3,755 4,973 5,381 5,658 5,751 5,929 5,773
Net Cash position 1 - - - - - - -
Leverage (Debt/EBITDA) 2.316 x 2.558 x 2.097 x 2.016 x 2.316 x 2.163 x 1.927 x
Free Cash Flow 1 2,035 1,767 2,235 2,708 947 1,253 1,475
ROE (net income / shareholders' equity) 18.5% 17.5% 28.2% 43.5% 24.7% 22.3% 21.9%
ROA (Net income/ Total Assets) 10.4% 10.5% 13% 15.9% 10.4% 9.57% 9.22%
Assets 1 9,359 5,884 330.2 7,130 10,157 12,581 14,052
Book Value Per Share 2 16.30 16.90 15.70 16.90 22.20 24.10 26.40
Cash Flow per Share 2 5.420 3.320 3.530 4.960 3.920 4.120 -
Capex 1 - 2,192 1,742 2,116 1,500 1,500 1,500
Capex / Sales - 95.74% 77.86% 89.85% 56.42% 50.88% 47.18%
Announcement Date 2/17/21 2/15/22 2/15/23 2/15/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Royalty Pharma plc

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
28 USD
Average target price
45.4 USD
Spread / Average Target
+62.14%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ROYALTY PHARMA PLC Stock Royalty Pharma plc
-0.32% 12.63B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. RPRX Stock
  4. Financials Royalty Pharma plc